Article Text

Download PDFPDF

S6D:7 Novel alpha-1-antitrypsin fragment as potential treatment of systemic lupus erythematosus
  1. U Wormser1,
  2. B Brodsky1,
  3. Y Finkelstein2,
  4. E Shapira1 and
  5. E Proscura1
  1. 1The Hebrew University, Jerusalem, Israel
  2. 2Shaare Zedek Medical Centre, Jerusalem, Israel


Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by a loss of immunologic tolerance, production of auto-antibodies and inflammatory damage in multiple organs. We have tested the effect of a novel anti-inflammatory peptide, a fragment of alpha-1-antitrypsin, termed UBE on two animal models of SLE, MRL/lpr and NZBW/F1 mice. Treatment of MRL/lpr mice with low dose of UBE (1 microgram/kg) at early stage of disease namely, 12 weeks old mice, caused significant reduction in proteinuria and hematuria. The beneficial effect of the peptide was corroborated by histological examination. Furthermore, a significant reduction in serum IL17, IL12 and anti dsDNA antibodies was observed in the UBE-treated mice. Isolated CD4 cells incubated with the peptide showed similar cytokine profile. Decreased levels of double negative CD4-CD8- and B220+cells were determined in lymph organs of UBE-treated animals. Similar effects were observed with NZBW/F1 mice, namely, the peptide (0.3 microgram/kg) caused significant reduction in proteinuria and, kidney and lung damage as determined in histopathological examination. The highly important SLE serum factor B-lymphocyte stimulator (BLyS or BAFF) was dramatically decreased in UBE-treated mice. Spleen and blood double negative CD4-CD8- and serum IL6, IP10 and MCP1 were significantly reduced in peptide-treated mice. The beneficial effects of UBE suggest this peptide as potential drug for SLE.

  • lupus
  • peptides
  • BLys

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.